PubMed · 15535430
Bazedoxifene (Wyeth).
Abstract
Bazedoxifene is a tissue-specific selective estrogen receptor modulator being developed by Wyeth Pharmaceuticals (formerly Wyeth-Ayerst Laboratories) to be used alone for the prevention and treatment of osteoporosis in postmenopausal women and in combination with Premarin for menopausal symptoms. As of March and June 2004, worldwide phase III trials for bazedoxifene, and bazedoxifene in combination with Premarin, were ongoing.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Christian Gruber, Doris Gruber. 2004. Bazedoxifene (Wyeth).. https://pubmed.ncbi.nlm.nih.gov/15535430/
Cite the original work for its findings. Save a collection to share your selection of sources.